Gadolinium based contrast agents that are used in MRIs have been linked with Nephrogenic Systemic Fibrosis(NSF)/Nephrogenic Fibrosing Dermopathy (NFD) in patients with kidney disease. Recently, the FDA released information that suggests MRAs, a variation of MRIs, that use gadolinium based contrast agents may pose more of a risk of causing NSF than they do in traditional MRIs.
MRAs provide information that isn't given in an ultrasound, X-ray or CT scan. Although this infomation is important in detecting aneurysms, blood clots, and plaquw buildup in blood, the dangers of gadolinium based contrast agents can't be ignored.
In order to be effective in an MRA, three times the approved amount of
gadolinium must be injected before the MRA takes place. This amount of gadolinium can easily cause cases of NSF and NSD.
For more information contact the
Gadolinium Lawyers at Williams Kherkher by calling 1-800-220-9341.